The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

CMS ends Biden-era proposal to expand Medicare coverage of anti-obesity drugs. Seniors continue paying out of pocket for ...

Get Instant Summarized Text (Gist) Expanding access to anti-obesity medications could yield a 13% annual return on investment for society by increasing life expectancy and reducing obesity-related ...

The benefits consultant Mercer has said that 44% of U.S. companies with 500 or more employees covered obesity drugs last year. Medicare does pay for drugs like Wegovy for patients who have heart ...

Expanding access to anti-obesity medications for all adults without diabetes who qualify would generate $10 trillion in social value by enabling people to live longer and healthier lives ...

Adding an anti-obesity medication just one month after behavioral therapy begins—rather than waiting the currently recommended six months—can more than double weight loss for patients who ...

high-demand obesity treatments under the federal government's Medicare program. The Centers for Medicare and Medicaid Services said late Friday that it would not cover the medications under ...

The benefits consultant Mercer has said that 44% of U.S. companies with 500 or more employees covered obesity drugs last year. Medicare does pay for drugs like Wegovy for patients who have heart ...

are denied coverage for anti-obesity medications, even though these treatments have been shown to reduce weight, improve overall health, prevent or manage obesity-related conditions, and for some ...